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N6-methyl-adenosine (m6A) is the most abundant
modification on messenger RNAs and is linked to
human diseases, but its functions in mammalian
development are poorly understood. Here we reveal
the evolutionary conservation and function of m6A
by mapping the m6A methylome in mouse and hu-
man embryonic stem cells. Thousands of messenger
and long noncoding RNAs show conserved m6A
modification, including transcripts encoding core
pluripotency transcription factors. m6A is enriched
over 30 untranslated regions at defined sequence
motifs and marks unstable transcripts, including
transcripts turned over upon differentiation. Genetic
inactivation or depletion ofmouse and humanMettl3,
one of the m6A methylases, led to m6A erasure on
select target genes, prolonged Nanog expression
upon differentiation, and impaired ESC exit from
self-renewal toward differentiation into several line-
ages in vitro and in vivo. Thus, m6A is a mark of
transcriptome flexibility required for stem cells to
differentiate to specific lineages.
INTRODUCTION
Reversible chemical modifications on messenger RNAs
(mRNAs) have emerged as prevalent phenomena that may
open a new field of ‘‘RNA epigenetics,’’ where RNA modifica-
tions have an impact akin to the diverse roles that DNAmodifica-
tions play in epigenetics (reviewed by Fu and He, 2012; Sibbritt
et al., 2013). N6-methyl-adenosine (m6A) is the most prevalent
modification of mRNAs in somatic cells, and dysregulation of
this modification has already been linked to obesity, cancer,
and other human diseases (Sibbritt et al., 2013). m6A has beenCellobserved in a wide range of organisms, and the methylation
complex is conserved across eukaryotes. In budding yeast,
the m6A methylation program is activated by starvation and
required for sporulation. In Arabidopsis thaliana, the methylase
responsible for m6A modification, MTA, is essential for
embryonic development, plant growth, and patterning, and the
Drosophila homolog IME4 is expressed in ovaries and testes
and is essential for viability (reviewed in Niu et al., 2013).
While m6A has been suggested to affect almost all aspects of
RNA metabolism, the molecular function of this modification re-
mains incompletely understood (Niu et al., 2013). Importantly,
m6A modifications are reversible in mammalian cells. Two
members of the alpha-ketoglutarate-dependent dioxygenases
protein family, fat-mass and obesity associated protein (FTO)
and ALKBH5, have been shown to act as m6A demethylases
(Jia et al., 2011; Zheng et al., 2013). Manipulating global m6A
levels has implicated m6A modifications in a variety of cellular
processes, including nuclear RNA export, control of protein
translation, and splicing (reviewed in Meyer and Jaffrey, 2014).
Recently, m6A modification has been suggested to play a role
in controlling transcript stability because the YTH domain family
of ‘‘reader’’ proteins specifically bind m6A sites and recruit the
transcripts to RNA decay bodies (Kang et al., 2014; Wang
et al., 2014a).
Whereas the DNAmethylome undergoes dramatic reprogram-
ming during early embryonic life, the developmental origins and
functions of m6A in mammals are incompletely understood.
Furthermore, the degree of evolutionary conservation of m6A
sites is not known in ESCs. To date, the functions of m6A in
mammalian cells have only been examined by RNAi knockdown.
Depletion of METTL3 and METTL14 in human cancer cell lines
led to decreased cell viability and apoptosis, leading to the inter-
pretation that m6A is important for cell viability (Dominissini et al.,
2012; Liu et al., 2014). A recent study reported that depletion of
Mettl3 inhibited mouse ESC (mESC) proliferation and led to
ectopic differentiation (Wang et al., 2014b). Here we assess
the conservation of the m6A methylome at the level of gene
targets and function in mESCs and human ESCs (hESCs). WeStem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc. 707
Figure 1. Topology and Characterization of
m6A Target Genes
(A) UCSC Genome browser plots of m6A-seq
reads along indicated mRNAs. Gray reads are
from non-IP input libraries and red reads are from
anti-m6A IP libraries. The y axis represents
normalized number of reads. Blue thick boxes
represent the open reading frame while the blue
line represents the untranslated regions. See also
Figure S1A, Table S1, and Table S2.
(B) Model of genes involved in maintenance of
stem cell state (adapted from Young, 2011). Red
hexagons represent modified mRNAs.
(C) Heatmap with log10 (p value) of gene set
enrichment analysis for m6A modified genes.
(D) Sequence motif identified after analysis of m6A
enrichment regions.SeealsoFiguresS1BandS1C.
(E) Normalized distribution of m6A peaks across 50
UTR, CDS, and 30UTR of mRNAs for peaks com-
mon to all samples.
(F) Graphical representation of frequency of
m6A peaks and methylation motifs in genes,
divided into five distinct regions.
(G) Distribution of m6A peaks across the length of
mRNAs (n = 5,070) and noncoding RNAs (n = 51).
See also Figures S1D–S1H.
(H) Scatter plot representation of m6A enrichment
score (on the x axis) and gene expression level (on
the y axis) for each m6A peak. See also Figure S1I.
(I) Box plot representing the half-life for transcripts
with at least one modification site and transcripts
with no modification site identified. p value
calculated by Wilcoxon test. See also Figures S1J
and S1K.
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m6A Controls Cell Fate Transitions in ESCsreport the consequences of genetic ablation ofMettl3 in mESCs
as well as depletion ofMETTL3 in hESCs. These experiments led
to the unexpected finding that m6A and METTL3 in particular are
not required for ESC growth but are required for stem cells to
adopt new cell fates.
RESULTS
Thousands of mESC Transcripts Bear m6A
To understand the role of the m6A RNA modification in early
development, we mapped the locations of m6A modification
across the transcriptome of mESCs and hESCs by m6A RNA708 Cell Stem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc.immunoprecipitation sequencing (RIP-
seq) as described elsewhere (Dominissini
et al., 2012; Meyer et al., 2012; Experi-
mental Procedures). For each experi-
ment, libraries were built for multiple
biological replicates and concordant
peaks for each experiment were used
for subsequent bioinformatics analyses.
In mESCs, m6A-seq revealed a total of
9,754 peaks in 5,578 transcripts (average
2 peaks per transcript), including 5,461
mRNAs (of 9,923 mRNAs) and 117 long
noncoding RNAs (lncRNAs). Due to the
lower expression levels of lncRNA as a
class, our approach likely underestimatesthe fraction of modified noncoding transcripts (Table S1 avail-
able online). Thus, thousands of mESC transcripts, including
mRNAs and lncRNAs, are m6A modified.
m6A in mRNAs of mESC Core Pluripotency Factors
We found that mRNAs encoding the core pluripotency regulators
in mESCs, including Nanog, Klf4,Myc, Lin28,Med1, Jarid2, and
Eed, were modified with m6A (Dunn et al., 2014; Young, 2011),
whereas Pou5f1 (also known as Oct4) lacked m6A modification
(Figures 1A and 1B). We confirmed m6A-seq results with inde-
pendent m6A-IP-qRT-PCR. (Figure S1A available online) and
m6A-IP followed by Nanostring nCounter analysis (m6A-string)
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data are accurate and robust. The top group of modified genes,
based on degree of modification, was enriched for several func-
tional groups, including chordate embryonic development, em-
bryonic development, gastrulation, and cell cycle (Figure 1C).
Thus, in mESCs, m6A targets include the ESC core pluripotency
network and transcripts with dynamically controlled abundance
during differentiation.
m6A Location and Motif in mESCs Suggest a Common
Mechanism Shared with Somatic Cells
De novo motif analysis of mESC m6A sites specifically identified
a previously described RRACU m6A sequence motif in somatic
cells (Figures 1D and S1B) (reviewed in Meyer and Jaffrey,
2014). Furthermore, as in somatic cells, m6A sites in mESCs
are significantly enriched near the stop codon and beginning of
the 30 UTR of protein coding genes (Figures 1E and 1F), as pre-
viously described for somatic mRNAs. Although the largest frac-
tion of m6A sites was within the coding sequence (CDS, 35%),
the stop codon neighborhood is most enriched, comprising
33% of m6A sites while representing 12% of the motif occur-
rence. In genes with only one modification site, this bias is
even more pronounced (Figure 1F). Comparison of transcript
read coverage between input and wild-type (WT) revealed no
bias for read accumulation around the stop codon in the input
sample (Figure S1C).
In addition to the last exon, which often includes the stop
codon and 30 UTR, we found a strong bias for m6A modification
occurring in long internal exons (median exon length of 737 bp
versus 124 bp; p < 2.2 3 1016; two-sided Wilcoxon test), even
when the number of peaks per exon was normalized for exon
length or motif frequency (Figures S1D–S1F). These results sug-
gest the possibility that processing of long exons is coupled
mechanistically to m6A targeting through as yet unclear systems
and/or that m6A modification itself may play a role in controlling
long exon processing. The topological enrichment of m6A peaks
surrounding stop codons in mRNAs is a poorly understood
aspect of the m6A methylation system. We sought to under-
stand if there was a topological enrichment or constraint on
m6A modification in noncoding RNAs (ncRNAs), which lack
stop codons. We parsed both classes of RNAs with three or
more exons into three normalized bins: the first, all internal,
and last exon. We observed an enrichment of m6A near the
last exon-exon splice junction for both coding RNAs and
ncRNAs and toward the 30 end of single-exon genes (Figures
1G and S1G–S1H), suggesting that the 30 enrichment of m6A
peaks can occur independently of translation or splicing.
Together, the location and sequence features we identified in
mESCs suggest a mechanism for m6A deposition that is similar
if not identical in somatic cells.
m6A Is a Mark for RNA Turnover
We next tested if transcript levels are correlated with the pres-
ence of m6A modification. Comparison of m6A enrichment level
versus the absolute abundance of RNAs revealed no correlation
between level of enrichment and gene expression (Figure 1H). A
separate, quartile-based analysis found a higher percentage of
m6A-modified transcripts in the middle quartiles of transcript
abundance (Figure S1I). Thus, our analysis suggests that m6ACellmodification is not simply a random modification that occurs
on abundant cellular transcripts; rather, m6A preferentially marks
transcripts expressed at a medium level.
To further define potential mechanisms of m6A function, we
asked whether m6A-marked transcripts differ from unmodified
transcripts at the level of transcription, RNA decay, or transla-
tion by leveraging published genome-wide data sets in mESCs.
RNA polymerase II (Poll II) occupancy at the promoters encod-
ing both unmodified and m6A-marked RNAs is similar (Fig-
ure S1J). In contrast, m6A-marked transcripts had significantly
shorter RNA half-life—2.5 hr shorter on average (p < 2.216, Fig-
ure 1I)—and increased rates of mRNA decay (average decay
rate of 9 versus 5.4 for m6A versus unmodified, p < 2.216).
m6A modified transcripts have slightly lower translational effi-
ciency than unmodified transcripts (1.32 versus 1.51, respec-
tively) (Ingolia et al., 2011) (Figure S1K). These results suggest
that m6A is a chemical mark associated with transcript turnover.
Mettl3 Knockout Decreases m6A and Promotes ESC
Self-Renewal
To understand the role of m6A methylation in ESC biology, we
chose to inactivate Mettl3, encoding one of the components of
the m6A methylase complex. To date no genetic study ofMettl3
has been performed to rigorously define its requirement for
m6A modification; all studies have relied on knockdown. We tar-
geted Mettl3 by CRISPR-mediated gene editing and generated
several homozygous Mettl3 knockout (KO) mESC lines. DNA
sequencing confirmed homozygous stop codons that terminate
translation within the first 75 amino acids, and immunoblot anal-
ysis confirmed the absence of METTL3 protein (Figures 2A and
S2A). Two-dimensional thin layer chromatography (2D-TLC)
showed a significant (60%) but incomplete reduction of m6A
in Mettl3 KO mESC (Figures 2B and S2B). Contrary to a recent
publication (Wang et al., 2014b), Mettl3 KO slightly reduced,
but did not prevent, the stable accumulation of METLL14 (Fig-
ure S2C). These experiments provide formal genetic proof that
METTL3 is a major, but not the sole, m6A methylase in mESCs.
Contrary to the expectation in the literature, the Mettl3 KO
mESCs are viable and, surprisingly, demonstrated improved
self-renewal.Mettl3 KOmESCs could be maintained indefinitely
over months and exhibited low levels of apoptosis, similar to WT
mESCs, as judged by PARP cleavage and Annexin V flow cytom-
etry (Figures 2A and S2D). We next asked whether Mettl3 KO
affected the ability of stem cells to remain pluripotent. Mettl3
KO mESC colonies were consistently larger than WT ESCs
and retained the round, compact ESC colony morphology with
intense alkaline phosphatase staining, comparable to WT col-
onies, as well as uniform expression of NANOG and OCT4 (Fig-
ures 2C–2E and S2E and data not shown). Quantitative cell pro-
liferation assay confirmed the increased proliferation rate of KO
over WT mESCs (Figure 2F). These observations suggest that
Mettl3KO enables enhancedmESC self-renewal. To rule out po-
tential off-target effects from CRISPR-mediated gene targeting,
we used an orthogonal approach to knock down Mettl3 in
mESCs. Two independent short hairpin RNAs (shRNAs) knocked
down Mettl3 to 20% (Figure S2F). 2D-TLC showed an 40%
loss of m6A in poly(A) RNAs (Figure S2G), and apoptosis assays
confirmed lack of cell death induction. Importantly,Mettl3 deple-
tion also increased mESC proliferation compared to controlStem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc. 709
Figure 2. Characterization of Mettl3 KO
Cells
(A) Western blot for METTL3 and PARP in WT and
two cell lines with CRISPR-induced loss of protein
(DD: DNA damaging agent). ACTIN is used as
loading control. See also Figure S2A.
(B) m6A ratio determined by 2D-TLC in WT and
Mettl3KO. Error bars represent standard deviation
of three biological replicates in all panels. See also
Figures S2B and S2C.
(C) Alkaline phosphatase staining of WT and
Mettl3 KO cells. See also Figures S2D and S2E.
(D) Box plot representation of colony radius for
WT and Mettl3 mutant cells. Experiments were
performed in triplicate, with at least 50 colonies
measured for each replicate.
(E) NANOG staining of colonies of WT and two cell
lines with CRISPR-induced loss of protein.
(F) Cell proliferation assay of WT and two cell lines
with CRISPR-induced loss of METTL3 protein.
See also Figures S2F–S2H.
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m6A Controls Cell Fate Transitions in ESCsshRNA for one hairpin (Figure S2H). Thus, two independent ap-
proaches confirm thatMettl3 inactivation enhanced self-renewal
of ESCs.
Mettl3 KO Blocks Directed Differentiation In Vitro and
Teratoma Differentiation In Vivo
These findings, coupled with the observation that modified
genes tend to have a shorter half-life, suggest that METTL3,
and by extension m6A, is needed to fine-tune and limit the level
of many ESC genes, including pluripotency regulators. Since
Mettl3 KO cells are capable of self-renewal, we tested their ca-
pacity for directed differentiation in vitro toward two lineages:
cardiomyocytes (CMs) and the neural lineage. While theWT cells
were able to generate beating CMs (50% of colonies), only
3%ofMettl3KO colonies of two independent clones produced
beating CMs. Furthermore, differentiated colonies of Mettl3 KO
cells retained high levels of Nanog expression but lacked ex-
pression of the CM structural protein Myh6, reflecting a larger
number of cells that failed to exit the mESC program in the
mutant cells (Figure 3A, Movie S1, and Movie 2). Similarly,
upon directed differentiation to the neural lineage, we observed
a marked difference between the ability of the two cells types to
differentiate. To assay for neural differentiation we stained for
TUJ1, a beta-3 tubulin expressed in mature and immature neu-
rons. While 53% of WT colonies had TUJ1+ projections, less
than 6% of Mettl3 KO colonies had TUJ1+ projections in both
KO clones (Figure 3B). Additionally, differentiated Mettl3 KO
cells showed an impaired ability to repress Nanog and activate
Tuj1 mRNA (Figure 3B).
To confirm the role of METTL3 in mESC differentiation in vivo,
we injected Mettl3 KO or WT cells subcutaneously into the right
or left flank, respectively, of SCID/Beige mice (n = 5). Both WT
and Mettl3 KO cells formed tumors consistent in morphology
with teratomas. Mutant tumors tended to be larger, in accor-710 Cell Stem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc.dance with mutant cell growth curves
observed in vitro (Figure 3C). Histological
analysis of H&E stained tumor sections
revealed consistent differences betweenthe two populations. While both groups of cells formed tera-
tomas that contained some degree of differentiation into
all three germ layers, the teratomas derived from KO cells were
predominantly composed of poorly differentiated cells with
very high mitotic indices and numerous apoptotic bodies,
whereas WT cells differentiated predominantly into neuroecto-
derm (Figure 3D). Analysis of adjacent sections revealed that
the mutant teratomas have markedly higher staining of the pro-
liferation marker KI67 and the ESC protein NANOG, which high-
light the poorly differentiated cells (Figures 3E, 3F, and S3A).
Mettl3 KO tumors had higher levels of Nanog, Oct4, and Ki67
mRNAs and lower levels of Tuj1,Myh6, and Sox17mRNAs (Fig-
ure S3B). These results suggest that insufficient m6A leads to a
block in ESC differentiation and persistence of a stem-like, highly
proliferative state.
Mettl3 Target Genes in mESCs
The incomplete loss of bulk m6A in Mettl3 KO cells may result
because METTL3 is solely responsible for the methylation of a
subset of genes or sites and/or because METTL3 functions in
a redundant fashion with anothermethylase on all m6A-modified
genes. To distinguish between these possibilities, we mapped
them6Amethylome inMettl3 KO cells. Comparison of the meth-
ylomes of WT versusMett3 KOmESCs revealed a global loss of
methylation across m6A sites identified in WT (Figure 4A). We
detected changes in 3,739 sites (in 3,122 genes), including
modification sites in NanogmRNA. Thus, this unbiased analysis
suggested a set of targets that rely more exclusively on
METTL3, including Nanog and other pluripotency mRNAs (Fig-
ures 4B and 4C) (Table S1). Gene set enrichment analysis
confirmed that METTL3-target genes significantly overlap func-
tional gene sets important for pluripotency, including targets
of CTNNB1 (4.43 3 106), targets of SMAD2 or SMAD3
(1.03 3 1016), targets of MYC (9.20 3 1010), targets of
Figure 3. Mettl3 Loss of Function Impairs ESCAbility to Differentiate
(A) Percentage of embryoid bodies with beating activity in Mettl3 KO and WT
control cells (right panel). Representative images of bodies stained for MHC
and DAPI (center panel) and mRNA levels of Nanog and Myh6, measured by
qRT-PCR, inMettl3 KO cells in relation to WT control cells are also displayed.
Error bars, standard deviation of three biological replicates in all panels. *p <
0.05, t test (two-tailed). See also Movie S1 and Movie S2.
(B) Percentage of colonies with TUJ1 projections inMettl3 KO and WT control
cells (right panel). Representative images of bodies stained for TUJ1 and DAPI
(center panel) and mRNA levels of Nanog and Tuj1, measured by qRT-PCR, in
Mettl3 KO cells in relation to WT control cells are also shown. *p < 0.05, t test
(two-tailed).
(C) Weight differences between teratomas generated from WT andMettl3 KO
cells. Tumors are paired by animal (n = 5) *p <0.1, calculated by Wilcoxon
matched pair signed ranked test.
(D) Representative sections of teratomas stained with H&E at low magnifica-
tion. Scale bar represents 1,000 mm. See also Figure S3A.
(E and F) Immunohistochemistry with antibody against KI67 (E) and with anti-
body against NANOG (F). Scale bar represents 100 mm. See also Figure S3B.
Figure 4. Impact of Loss of Mettl3 on the mESC Methylome
(A) Cumulative distribution function of log2 peak intensity of m6A modified
sites.
(B) Sequencing read density for input (gray) versus in m6A-IP (red) for Nanog. y
axis represents normalized number of reads. Gene model is as in Figure 1A.
(C) Heatmap representing IP enrichment values for peaks with statistically
significant difference between WT and Mettl3 mutant. Bar to the right repre-
sent genes in each data set with a >1.5-fold decrease in IP enrichment values.
(D) Model of genes involved in maintenance of stem cell state (adapted
from Young, 2011), representing transcripts with loss of m6A modification in
Mettl/ cells.
(E) Percentage of input recovered after m6A-IP measured by Nanostring for
each mRNA. Error bars, standard deviation of two biological replicates. *p <
0.05, t test (two-tailed).
(F) mRNA levels of Nanog and Oct4, measured by qRT-PCR, after Pol II inhi-
bition relative to untreated sample in WT and Mettl3 KO cells. Error bars,
standard deviation of three biological replicates. *p < 0.05, t test (two-tailed).
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m6A Controls Cell Fate Transitions in ESCsSOX2 (4.75 3 108), and targets of NANOG (7.18 3 108) (Fig-
ure 4C), and include 5 of 11 core ESC regulators such asNanog,
Rlf1, Jarid2, and Lin28 (Figure 4D). Independent validation byCellm6A RIP followed by Nanostring detection confirmed loss
of m6A in Nanog and other mRNAs in KO versus WT mESCs
(Figure 4E). Further, after transcription arrest by flavopiridol
treatment, Nanog mRNA showed delayed turnover in Mettl3
KO cells compared to WT, consistent with a requirement for
m6A in Nanog mRNA turnover (Figure 4F). However, RNA-seq
analysis of Mettl3 KO cells revealed modest perturbations in
mRNA steady state levels with only 300 genes demonstratingStem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc. 711
(legend on next page)
Cell Stem Cell
m6A Controls Cell Fate Transitions in ESCs
712 Cell Stem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc.
Cell Stem Cell
m6A Controls Cell Fate Transitions in ESCssignificant changes over 1.5-fold. Collectively, these results
suggest that ESC genes are under METTL3 control and that
m6A impacts ESC biology.
Widespread m6A Modification of hESCs
The identification of thousands of m6A sites raises the challenge
of defining the functional importance of each and every one of
the sites. We reasoned that evolutionary conservation provides
a powerful and comprehensive metric of function. To this end,
we mapped m6A sites in hESCs and during endoderm differenti-
ation to elucidate the patterns and potential conservation of
m6A methylome (Figure 5A). In basal state hESCs [Time (T) =
0], m6A-seq identified 16,943 peaks in 7,871 genes representing
7,530 coding and 341 noncoding RNAs. Upon hESC differentia-
tion toward endoderm (T = 48, ‘‘endoderm differentiation’’ there-
after), m6A-seq identified 15,613 m6A peaks in 7,195 genes
representing 6,909 coding and 286 noncoding RNAs (Table
S3). As shown in Figure 5B, 11,322 peaks (6,004 genes) were
common between the undifferentiated and differentiated hESCs,
while 5,348 (3,979 genes) versus 4,087 peaks (3,024 genes) were
unique, respectively.
Many Master Regulators of hESC Maintenance and
Differentiation Are Modified with m6A
As we observed for mESC, transcripts encoding many hESC
master regulators, including human NANOG, SOX2, and
NR5A2, were m6A modified. As in mESCs, the transcripts for
OCT4 (POU5F1) in hESCs did not harbor an m6A modification
(Figure 5D). These results show that in both organisms the
core pluripotency/maintenance genes are under the regulatory
influence of the m6A pathway. We also identified human-specific
lncRNAs with known roles in hESC maintenance, such as LINC-
ROR andMEGAMIND/TUNA, to contain m6A modifications (Fig-
ures 5D and S4A) (Lin et al., 2014; Loewer et al., 2010). Upon
induction of hESC differentiation, we observed transcripts en-
coded by several key regulators of endodermal differentiation,
includingEOMES and FOXA2 (Figure 5D), to also havem6Amod-
ifications. Gene ontology (GO) analyses of methylated genes in
undifferentiated hESCs, and after endodermal differentiation,
were significantly enriched in biological functions such as regu-
lation of transcription (FDR = 1.2 3 1014), chordate embryonicFigure 5. m6A-seq Profiling of hESCs during Endoderm Differentiation
(A) m6A-seq was performed in resting (undifferentiated) human H1-ESCs (T0) an
(B) Venn diagram of the overlap between high-confidence T0 and T48 m6A peaks.
S3 and Table S4.
(C) Sequence motif identified after analysis of m6A enrichment regions.
(D) UCSC Genome browser plots of m6A-seq reads along indicated RNAs. Gray r
from anti-m6A IP libraries. y axis represents normalized number of reads; x axis is
regulators of endoderm differentiation (right) are represented. See also Figure S4
(E) Scatter plot of m6A peak intensities between two different time points (T0 vers
specific peaks supported by both biological replicates highlighted.
(F) UCSC Genome browser plots of m6A-seq reads along indicated mRNAs in und
IP control input libraries. The red and blue reads are from the anti-m6A RIP of T
(G) Differential intensities of m6A peaks (DMPIs) identify hESC cell states T0 ve
according to the legend. The peaks and samples are both clustered by average lin
intensity as the distance metric.
(H) Number of peaks per exon normalized by the number of motifs (on sense stran
bootstrapping.
(I) The normalized distribution of m6A peaks across the 50 UTR, CDS, and 30 UTR
(J) Box plot representing the half-life for transcripts, with transcripts separated a
Celldevelopment (FDR = 1.13 104), and regulation of cell morpho-
genesis (FDR = 0.01).
Upon hESC differentiation toward endoderm, 1,356 peaks in
1,137 genes showed quantitative differences of at least 1.5-
fold in m6A intensity, after normalization for input transcript
abundance (Figures 5E and 5F and Table S4). The majority of
these differential m6A sites represented quantitative differences
at existing sites (i.e., 59.1% of the peaks were called in both time
points), rather than state-specific de novo appearance or
erasure of modification (Figure 5G). This is consistent with the
observation that 74.9% of sites in the hESCs overlapped those
observed in HEK293T data (Meyer et al., 2012) and the minimal
changes in m6A sites observed in a recent survey of m6A pattern
across cell types (Schwartz et al., 2014). We suggest that
transcripts exhibit dynamic differential peak m6A methylation
intensity largely at ‘‘hard-wired sites’’ during differentiation under
the conditions examined and when compared to other tissue
types.
Conserved Features of m6A Modifications Spanning
Different Species
We found that three salient features of the m6A methylome are
conserved in hESCs. First, m6A sites in hESCs are also domi-
nated by the RRACU motif seen in mESC and somatic cells
(Dominissini et al., 2012; Meyer et al., 2012) (Figure 5C). There
was also a strong preference for the methylome to target long-
internal exons at the RRACU motif even after we normalized
for exon length and number of m6A motifs (Figure 5H). Sec-
ond, there was a significant enrichment in m6A peaks at the
30 end of transcripts, near the stop codon of coding genes
or the last exon in noncoding RNAs (Figures 5I and S4B–
S4D). Furthermore, the topology of m6A modification is pre-
served upon endodermal differentiation (Figure 5I). As in
mESCs, moderately to lowly expressed genes have higher
probabilities of becoming methylated (Figure S4E). Lastly,
hESC m6A is not correlated with transcription rate as judged
by Global Run-On sequencing (GRO-seq) (Sigova et al.,
2013), but it is strongly anticorrelated with measured mRNA
half-life in human pluripotent cells (Neff et al., 2012), strongly
suggesting that m6A modification also marks RNA turnover
in hESCs (Figures 5J, S4F, and S4G).d after 48 hrs of Activin A induction toward endoderm (mesoendoderm) (T48).
The number of genes in each category is shown in parenthesis. See also Table
eads are from non-IP control input libraries and red (T0) or blue (T48) reads are
genomic coordinates. Key regulators of stem cell maintenance (left) andmaster
A.
us T48) of the same biological replicate with only ‘‘high-confidence’’ T0 or T48
ifferentiated (T0) versus differentiated (T48) cells. The gray reads are from non-
= 0 and T = 48 samples, respectively.
rsus T48 hrs. Z score scaled log2 peak intensities of DMPIs are color-coded
kage hierarchical clustering using 1-Pearson correlation coefficient of log2 peak
d) in the exon. The error bars represent standard deviations from 1,000 times of
of mRNAs for T0 and T48 m6A peaks. See also Figures S4B–S4D.
ccording to enrichment score. See also Figures S4E, S4F, and S4G.
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Figure 6. Evolutionary Conservation and Divergence of the m6A Epi-transcriptomes of hESCs and mESCs
(A) Venn diagram showing a 62% overlap between methylated genes inMusmusculus (purple) and Homo sapiens (red) ESCs (p = 3.53 1092; Fisher exact test).
See also Table S5 and Table S6.
(B) The m6A peaks that could be mapped to orthologous genomic windows between mouse and human were identified. The intensities of m6A-seq signals in
hESCs and mESCs were shown for m6A peaks found to be unique in mouse (blue), unique in human (red), and conserved between human and mouse (black).
(C) Box plot of peak intensities of m6A sites conserved (‘‘common’’) or not conserved (‘‘specific’’) in mESCs and hESCs. (p = 1.3 3 1015 and 8.7 3 1023,
respectively, Wilcoxon test).
(D–F) UCSCGenome browser plots of m6A-seq reads along indicatedmRNAs. The gray reads are from non-IP control input libraries and the purple and red reads
are from the anti-m6A RIP of mESCs and hESCs (T0), respectively. (D) Mouse-specific m6Amodifications are represented. (E) Human-specific m6Amodifications
of ESCs are represented. (F) Conserved m6Amodifications at the gene and site level are represented. Genes such asCHD6 have a conserved m6A peak location
at its 30 UTR as well as mouse- and human-specific m6A peaks at conserved but distinct exons.
Cell Stem Cell
m6A Controls Cell Fate Transitions in ESCsEvolutionary Conservation and Divergence of the m6A
Epi-transcriptomes of Human and Mouse ESCs
Previous studies suggested significant conservation of m6A
modified genesbetweenmouseand human in somatic cell types,
but the comparisons are limited by nonmatched tissue types714 Cell Stem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier In(Dominissini et al., 2012; Meyer et al., 2012). We were thus inter-
ested in examining the evolutionary conservation of hESC and
mESC m6A methylomes. At the gene level, 69.4% (3,609 of
5,204) of hESC genes are also m6A modified in the orthologous
mouse gene (p = 8.3 3 10179; Fisher exact test) (Figure 6A;c.
Cell Stem Cell
m6A Controls Cell Fate Transitions in ESCsTable S5). Furthermore, we identified 632 conserved m6A peak
sites (46.1%) between hESCs and mESCs (Table S6). Notably,
conserved sites tend to have higher m6A peak intensities
compared to m6A peak sites that were not conserved (Figures
6B and 6C, p = 1.33 1015 and 8.73 1023 for hESCs ormESCs,
respectively; Wilcoxon test). Commonly methylated genes can
demonstrate m6A modification sites at identical sites (as in the
case of GLI1), similar but not identical locations (as in the case
of SOX2), or m6A sites at different exons (as in the case of
CHD6) (Figures 6D–6F and Table S4). Our data thus reveal a sub-
stantial overlapat thegene level, suggestingbroad functional sig-
nificance of m6A modification in ESCs in both species. At the
same time, we also observed numerous species-specific m6A
patterns that may contribute to specific aspects of ESC biology
(Schnerch et al., 2010).
METTL3 Is Required for hESC Differentiation
To address the function of m6A in hESCs, we generated hESC
colonies with stable knockdown of METTL3 and shRNA control
(Figure 7A). Knockdown of METTL3 in hESCs resulted in reduc-
tion inMETTL3mRNA levels and reduction in m6A level (Figures
7B and 7C and Figures S5B and S5C).METTL3-depleted hESCs
could be stably maintained, suggesting the dispensability of
METTL3 for hESC self-renewal or viability. Strikingly, differentia-
tion ofMETTL3-depleted hESCs into neural stem cells (NSCs) by
dual inhibition of SMAD signaling, using Dorsomorphin and SB-
431542, revealed a block in neuronal differentiation (Experi-
mental Procedures). While 44% (± 3.5% SD) of the control cells
were SOX1+, only 10% (± 3.1% SD) of the METTL3-depleted
were SOX+ (Figure S5A).
Similarly, knockdown of METTL3, in three independently
generated hESC colony clones selected for METTL3 knock-
down, led to a profound block in endodermal differentiation at
day 2 and day 4 based on their failure to express the endoderm
markers EOMES and FOXA2 compared to either two shRNA
control colony clones (Figure 7D) or WT hESCs (Figure S5D).
Consistently, METTL3-depleted ESCs retain high levels of
expression of the master regulators NANOG and SOX2
throughout the differentiation time course in contrast to their
diminishing expression in WT cells (Figures 7E and S5E). These
results indicate that METTL3 and m6A control differentiation of
hESCs.
DISCUSSION
m6A Methylome in ESCs
Our analysis of the ESC m6A methylome in mouse and human
cells reveals extensivem6Amodification of ESC genes, including
most key regulators of ESC pluripotency and lineage control.
However, this observation does not mean that m6A is uniquely
tied to the pluripotency network. Because m6A marks moder-
ately expressed transcripts that need to be turned over in a
timely fashion, such genes in ESCs likely include many regula-
tors of pluripotency and lineage determination. The pattern
and sequence motif associated with ESC m6A are similar if not
identical to those previously reported in somatic cells, suggest-
ing a single mechanism that deposits m6A modification in early
embryonic life. This invariant mechanism for m6A contrasts
with the complexity of 5-methyl-cytosine in DNA and histoneCelllysine methylations that undergo extensive reprogramming
with distinct rules in pluripotent versus somatic cells.
We identified a general and conserved topological enrichment
of m6A sites at the 30 end of genes among single-exon and mul-
tiple-exon mRNAs as well as ncRNAs. Thus, neither the stop
codon nor the last exon-exon splice junction can alone explain
the observed m6A topology in RNA. However, all species exam-
ined to date including Saccharomyces cerevisae and A. thaliana
exhibit a strong 30 bias in m6A localization, suggesting an evolu-
tionary constraint that may target the m6A modification to the 30
ends of genes regardless of gene structure or coding potential.
This bias may be achieved by preferential m6A methylase
recruitment to 30 sites or preferential action of demethylases in
upstream regions of the transcript. Although the role of demethy-
lases cannot be excluded, the observation of 30 end m6A bias in
S. cerevisiae, which lacks known m6A demethylases, argues
against the latter mechanism (Bodi et al., 2012; Jia et al., 2011;
Schwartz et al., 2013; Zheng et al., 2013). The functional impor-
tance of m6A location versus its specific molecular outcome
needs to be addressed in future studies.
Mettl3 Selectively Targets mRNAs, Including
Pluripotency Regulators
While several studies had approached Mettl3 function by RNAi
knockdown (Dominissini et al., 2012; Fustin et al., 2013; Liu
et al., 2014; Wang et al., 2014b), genetic ablation of Mettl3
allowed us to examine the true loss-of-function phenotypes.
The importance of using definitive genetic models is highlighted
by recent studies in the DNA methylation field where shRNA ex-
periments led to misassigned functions of Ten-eleven transloca-
tion (TET) proteins that were later recognized in genetic KOs
(Dawlaty et al., 2011, 2013). We found that both Mettl3 KO and
depletion led to incomplete reduction of the global levels of
m6A in both mESCs and hESCs, demonstrating redundancy in
m6A methylases. However, m6A profiling in Mettl3 KO cells re-
vealed a subset of targets, approximately 33% of m6A peaks,
that are preferentially dependent on METTL3, and these
includedNanog,Sox2, and additional pluripotency genes. A sec-
ond m6A methylase, METTL14, was described during the prep-
aration of this manuscript.
RNAi knockdown of METTL3 in somatic cancer cells led to
apoptosis (Dominissini et al., 2012), and one study reported
ectopic differentiation of mESCs with Mettl3 depletion (Wang
et al., 2014b). In contrast, we found that Mettl3 KO does not
affect mESC cell viability or self-renewal, and in fact mESCs
renewed at an improved rate. The differences in phenotype
observed could potentially be explained by different depen-
dency onm6Amodified RNAs in different cell types, acute versus
chronic inactivation, or RNAi off-target effects. m6A methylome
analysis in different cell types with Mettl3 inactivation may
shed light on these differences in the future.
Conservation of m6A Methylome in Mammalian ESCs
The conserved methylation patterns of many ESC master regu-
lators and the shared phenotype observed upon inactivation
of Mettl3 suggest that METTL3 operates to control stem cell
differentiation. It is known that hESCs and mESCs are not equiv-
alent (Schnerch et al., 2010) and are cultured in different condi-
tions. By focusing in on orthologous genes, we were able toStem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc. 715
Figure 7. METTL3 Is Required for Normal hESC Endoderm Differentiation: A Model of METTL3 Function
(A) hESC cells were transfected with anti-METTL3 shRNA (KD) as well as control shRNA and stable hESC colonies were obtained after drug selection. Two
independent clones were subjected to endodermal differentiation with Activin A and examined at various indicated time points. A schematic of the trends of gene
expression for indicated markers of stem maintenance and endoderm differentiation is also shown. See also Figure S5A.
(B) Levels of METTL3 mRNA in hESC cells with control shRNA versus anti-METTL3 shRNA (KD) across the three indicated time points during endodermal
differentiation (n = 2 independent generated ESC knockdown and control clones shown). In all panels, error bars represent standard deviation across three
replicates per time point; *p < 0.05 t test (two-tailed) between different clones. See also Figure S5B.
(C) Anti-m6A dot-blot was performed on 103 fold dilutions of poly(A)-selected RNA from hESCs derived from control shRNA versus anti-METTL3 shRNA clones.
See also Figure S5C.
(D and E) mRNA levels of endodermal and stem maintenance/marker genes. qRT-PCR was performed on indicated genes and time points (n = 2 independently
generated ESC knockdown and control clones shown). See also Figure S5D.
(F) Model: m6A marks transcripts for faster turnover. Upon transition to new cell fate, m6A marked transcripts are readily removed to allow the expression of new
gene expression networks. In the absence of m6A, the unwanted presence of transcripts will disturb the proper balance required for cell fate transitions.
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m6A Controls Cell Fate Transitions in ESCscatalog both shared and species-specific methylation sites. The
observation that certain methylation sites aremodifiedwhenever
a target transcript is expressed in both species, despite cell state
or culture differences, argues that these modification events
have been preserved under strong purifying selection during
evolution. Our comparative genomic analyses also pave the
way to further understand potential biological differences be-
tween hESCs and mESCs at the level of m6A epi-transcriptome,
given the unique patterns of somemethylation sites between the
species.
RNA ‘‘Antiepigenetics:’’ m6A as aMark of Transcriptome
Flexibility
Stem cell gene expression programs need to balance fidelity and
flexibility. On the one hand, stem cell genes need sufficient
stability to maintain self-renewal and pluripotency over multiple
cell generations, but on the other hand, gene expression needs
to change dynamically and rapidly in response to differentiation
cues. It has been proposed that ESC gene expression programs
are in constant flux between competing fates, and pluripotency
is a statistical average (Loh and Lim, 2011; Montserrat et al.,
2013; Shu et al., 2013). We found that mRNAs with m6A tend
to have a shorter half-life, and Nanog and Sox2 mRNAs could
not be properly downregulated with differentiation in METTL3-
deficient mESCs and hESCs. However, METTL3 deficiency
has only modest effects on steady state gene expression, which
could arise from the nonstoichiometric nature of the m6A modi-
fication. The application of methods that can determine the level
of modification of each RNA species will allow us to answer
these questions (Harcourt et al., 2013; Liu et al., 2013). Mettl3
KO mESCs have enhanced self-renewal but hindered differen-
tiation, concomitant with a decreased ability to downregulate
ESC mRNAs. WTAP, a conserved METTL3 interacting partner
from yeast to human cells (Horiuchi et al., 2013; Schwartz
et al., 2014), is also required for endodermal and mesodermal
differentiation (Fukusumi et al., 2008). The observed phenotypes
in ESCs and teratomas are all the more notable because we
have significantly reduced, but not eliminated, m6A.
Our findings suggest a model where m6A serves as the neces-
sary flexibility factor to counterbalance epigenetic fidelity—an
RNA ‘‘antiepigenetics’’ measure (Figure 7F). m6A marks a wide
range of transcripts, including ESC fate determinants to limit their
level of expression and ensure their continual degradation so that
cells can rapidly transition between gene expression programs.
In ESCs, m6A is required for cells to rapidly exit the pluripotent
state upon differentiation. The inability to exit the stem cell state
and continued proliferation upon insufficient m6A offers a poten-
tial explanation for the association of FTO with human cancers
(Loos andYeo, 2014). METTL3 depletion also leads to elongation
of the circadian clock (Fustin et al., 2013), suggesting a role for
m6A in resetting the transcriptome. In yeast, m6A is active during
meiosis (Clancy et al., 2002), where diploid gene expression
programs are reset to generate haploid offspring. We propose
that m6A makes the transition between cell states possible by
facilitating a reset mechanism between stages, as occurs in
ESCs and likely other cell types. In contrast to epigenetic mech-
anisms that provide cellular memory of gene expression states,
m6A enforces the transience of genetic information, helping cells
to forget the past and thereby embrace the future.CellEXPERIMENTAL PROCEDURES
For full details, see the Supplemental Experimental Procedures.
Mouse Cell Culture and Differentiation
J-1murine ESCswere grown under typical feeder-free ESC culture conditions.
For CM formation, mESCs were differentiated in CM differentiation media and
scored on day 12. For neuron formation, mESCs were differentiated in MEF
and ITSFn medium and scored after 10 days in ITSFn medium. For the cell
proliferation assay 5,000 cells were cultured in 24-well plates and the assay
was performed according to the manufacturer’s protocol (MTT assay, Roche).
For the single-colony assays and Nanog staining, 1,000 cells were cultured per
well, on a six-well plate. For alkaline phosphatase staining, cells were stained
according to the manufacturer’s protocol (Vector Blue Alkaline Phosphatase
Substrate Kit).
hESC Cell Culture, Transfection, and Differentiation
H1 (WA01) cells were cultured in feeder-free conditions as described else-
where (Sigova et al., 2013). Stable hESC lines were created that expressed
shMETTL3 RNA or scrambled shRNA by transfection of hESCs with plasmids
encoding shMETTL3 or scrambled shRNA and a puromycin resistance gene.
Cells were treated with puromycin for 6 days beginning 2 days after transfec-
tion. For scrambled shRNA and METTL3 shRNA, two and three independent
puromycin-resistant colonies were picked and expanded, respectively. Endo-
dermal differentiation was then induced by Activin A, as described elsewhere
(Sigova et al., 2013). Day 2 and Day 4 of differentiation weremeasured from the
time that Activin A was added. Puromycin was removed from the media 1 day
prior to endodermal differentiation.
RNA m6A-IP and m6A Methylation IP RNA-Seq Analysis
Libraries generated with iCLIP adaptors were separated by barcode, and
perfectly matching reads were collapsed. Sequencing reads weremapped us-
ing TopHat (Trapnell et al., 2009). A nonredundant mm9 transcriptome was
assembled fromUCSCRefSeq genes, UCSC genes, and predictions fromUlit-
sky et al. (2011) and Guttman et al. (2011). For human data sets, the Ensembl
genes (release 64) were used. We performed the search for enriched peaks by
scanning each gene using 100-nucleotide sliding windows and calculating an
enrichment score for each sliding window (Dominissini et al., 2012). HOMER
software package (Heinz et al., 2010) was used for de novo discovery of the
methylation motif.
CRISPR-Mediated Mettl3 KO
Plasmids for guide RNA (design with CRISPR design tool; Hsu et al., 2013), a
human codon optimized Cas9 expression plasmid, and a plasmid with a puro-
mycin resistance cassete were cotransfected. Cells were plated at low density
for single-colony isolation and selected single colonies were tested by western
blot for loss of protein.
Determination of m6A Levels
2D-TLC was performed as described by Jia et al. (2011). For dot-blots, the
indicated amounts of RNA were applied to the membrane and cross-linked
by UV. The m6A primary antibody was added at a concentration of 1:500.
The membrane was incubated with the secondary antibody and exposed to
an autoradiographic film. m6A RNA mass-spectrometry was performed as
described in the Supplemental Experimental Procedures.
Data Set Comparison
Mouse Pol II occupancy data, mRNA half-life, and protein translation efficiency
were obtained from Rahl et al. (2010), Sharova et al. (2009) and Ingolia et al.
(2011). Plotting and statistical tests were performed in R. Multidimensional
gene set enrichment analysis over DAVID GO terms and stem cell gene sets
(Wong et al., 2008) were performed using Genomica (Segal et al., 2003).
Teratoma Generation and Histopathology
WT and Mettl3 mutant cells were subcutaneously injected into 8-week-old
female SCID/Beige mice (Charles River). Four weeks after injection, the
mice were euthanized and the tumors were harvested. All animal studies
were approved by Stanford University IACUC guidelines. For histologicalStem Cell 15, 707–719, December 4, 2014 ª2014 Elsevier Inc. 717
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m6A Controls Cell Fate Transitions in ESCsanalysis, slides were stained with hematoxylin and eosin (H&E) or stained by
immunohistochemistry (IHC) with VECTASTAIN ABC Kit and DAB Peroxidase
Substrate Kit following the manufacturer’s instructions. Analyses were per-
formed by a boarded veterinary pathologist (D.M.B.).
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